AVTX

Avalo Therapeutics, Inc.

2 transactions on file, per SEC Form 4 filings.

Sullivan Christopher Ryan

Chief Financial Officer · 2026-09-10

Option exercise

$82K

Sullivan Christopher Ryan

Chief Financial Officer · 2026-09-10

Sold

$179K

Each row links to the underlying SEC filing. Sells are shown for transparency, not as a signal — see the insider trading article for why.

Is AVTX actually a buy?

Following an insider into a stock isn't a strategy on its own. Run your own margin-of-safety analysis, free.